Ozempic Shows Potential for Alcohol Addiction in Trial

[ad_1]

(MedPage Today) — Weekly treatment with low doses of the GLP-1 receptor agonist semaglutide (Ozempic) reduced alcohol consumption and craving in adults with alcohol use disorder (AUD), a phase II randomized trial showed.
At 9 weeks, semaglutide…

[ad_2]

Source link : https://www.medpagetoday.com/psychiatry/addictions/114191

Author :

Publish date : 2025-02-12 18:44:07

Copyright for syndicated content belongs to the linked Source.